Home / Themes / GLP-1 Long '24: GLP1 Drug Producer
Last updated
Theme thesis · 4/5 sections · Tickers 7 with notes
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
The current thesis on GLP-1 drug producers in Spring 2025 is bullish, driven by the increasing adoption and market expansion of GLP-1 drugs for various indicati
The current thesis on GLP-1 drug producers in Spring 2025 is bullish, driven by the increasing adoption and market expansion of GLP-1 drugs for various indications beyond diabetes, including obesity, NASH, and potentially Alzheimer'Äôs disease. The market dynamics are supported by strong clinical trial outcomes, significant demand from patients, and the development of oral formulations. However, rising competition and potential regulatory challenges pose risks to sustained dominance for existing market leaders.
There is strong clinical evidence supporting the efficacy of GLP-1 drugs in treating obesity and other comorbid conditions, which has driven increased adoption and expanded the addressable market.
Oral GLP-1 formulations are in development and expected to significantly increase patient compliance and market penetration.
Ongoing expansion of indications for GLP-1 drugs into areas like NASH and Alzheimer'Äôs disease could further boost market growth and revenue streams.
Increased competition from new entrants and alternative therapies could lead to market share erosion for current producers.
Regulatory scrutiny concerning long-term side effects and pricing pressures could impact profitability and market dynamics.
Supply chain constraints, particularly in autoinjector production, may limit the ability to meet rising demand efficiently.
Patient experiences, treatment discussions, side effects, new drug awareness, interest in new GLP-1s and dosing schedules
Weight loss journeys, GLP-1 efficacy, user reviews, lifestyle changes, interest in new GLP-1s and dosing schedules
Metric/field PCEHC (Personal Consumption Expenditures: Health Care)
Cadence monthly
Why it matters Directly reflects the overall spending by individuals on healthcare services and products, indicating the size and growth of the addressable market for GLP-1 drugs.
Signal to watch Sustained or increasing growth in PCEHC is bullish, suggesting a robust market for healthcare expenditures, including GLP-1s.
Confidence: high
Metric/field CPI for Medical Care Services (Series ID: CUUR0000SAM2) and Prescription Drugs (Series ID: CUUR0000SEMC04)
Cadence monthly
Why it matters Tracks inflation specifically for medical products and services, providing insight into potential pricing pressures and the cost environment for GLP-1 producers.
Signal to watch Lower or stable inflation in medical care and prescription drugs is bullish, indicating less pressure on drug pricing and potentially better profitability.
Confidence: high
Metric/field Advance Monthly Sales for Retail Trade and Food Services (excluding Food Services)
Cadence monthly
Why it matters Reflects broader consumer spending and disposable income, which can influence patient's ability to afford out-of-pocket costs for GLP-1 treatments or impact overall economic sentiment for healthcare spending.
Signal to watch Strong and consistent retail sales growth is bullish, suggesting a healthy consumer economy that can support elective or higher-cost treatments.
Confidence: medium
Metric/field Unemployment Rate (Series ID: LNS14000000)
Cadence monthly
Why it matters A lower unemployment rate generally correlates with higher rates of employer-sponsored health insurance, which is crucial for patient access and reimbursement of GLP-1 drugs.
Signal to watch A stable or declining unemployment rate is bullish, indicating broader insurance coverage and economic stability for patients.
Confidence: medium
Metric/field Medicare and Medicaid Outlays for Prescription Drugs
Cadence annually (with quarterly updates/projections)
Why it matters Directly impacts reimbursement and coverage for GLP-1 drugs, especially with the implementation of programs like the Medicare GLP-1 Bridge, influencing market access and revenue potential.
Signal to watch Increased or stable government outlays for prescription drugs, particularly for obesity or diabetes, is bullish, indicating supportive policy and funding for GLP-1 access.
Confidence: high
Metric/field Web Search Interest (relative volume) for 'Wegovy', 'Ozempic', 'Mounjaro', 'Zepbound', 'Foundayo', 'MariTide', 'Retatrutide', 'oral GLP-1', 'weight loss drug'
Cadence daily/weekly
Why it matters Reflects consumer awareness, interest, and demand for GLP-1 drugs and related treatments, indicating potential market adoption and patient engagement.
Signal to watch Sustained or increasing search interest for key GLP-1 brands and related terms is bullish, signaling growing market demand.
Confidence: high
Metric/field Status of Phase 3 trials for 'MariTide', 'Retatrutide', 'CT-388', 'Etavopivat', and other GLP-1 pipeline assets (e.g., 'Recruiting', 'Active, not recruiting', 'Completed', 'Terminated')
Cadence event_driven
Why it matters Provides real-time updates on the progress and potential delays of critical pipeline drugs, impacting future market entry and competitive landscape.
Signal to watch Advancement of trials to 'Completed' status or positive top-line results announcements are bullish, indicating progress towards regulatory approval.
Confidence: high
Metric/field Qualitative analysis of posts and comments in 'r/diabetes', 'r/loseit', 'r/obesity' related to GLP-1 drug efficacy, side effects, patient experiences, and access challenges
Cadence daily/weekly
Why it matters Offers direct, unfiltered insights into patient experiences, treatment satisfaction, side effect profiles, and real-world adoption barriers, complementing official data.
Signal to watch Predominantly positive sentiment, discussions on high efficacy, and manageable side effects are bullish, suggesting strong patient adherence and positive word-of-mouth.
Confidence: medium
Metric/field Press releases and database updates on new drug approvals, expanded indications, or safety warnings for GLP-1 receptor agonists
Cadence event_driven
Why it matters Directly impacts market entry, potential revenue streams, and public perception of GLP-1 drugs, addressing regulatory scrutiny and market expansion.
Signal to watch New approvals or expanded indications are bullish, opening new markets or patient populations. Safety warnings are bearish.
Confidence: high
Metric/field Articles and reports on competitive landscape, manufacturing capacity updates, supply chain issues, pricing debates, and market share shifts for GLP-1 producers
Cadence daily
Why it matters Provides a comprehensive overview of industry trends, competitive dynamics, and potential operational challenges or successes for GLP-1 drug producers.
Signal to watch News highlighting successful manufacturing scale-ups, strong market share gains, or favorable pricing trends is bullish. Reports of supply constraints or intense price wars are bearish.
Confidence: high
Metric/field Total Prescriptions (TRx) and New Prescriptions (NBRx) for 'Mounjaro', 'Zepbound', 'Foundayo', 'Wegovy', 'Ozempic', 'Rybelsus', 'MariTide', 'CT-388' in the U.S. and key international markets
Cadence weekly/monthly
Why it matters Provides direct, granular insight into market adoption, growth trajectory, competitive market share, and patient uptake for individual GLP-1 drugs.
Signal to watch Consistent growth in TRx and NBRx, especially for new launches or pipeline assets, and market share gains against competitors are bullish.
Confidence: high
Metric/field Alerts and reports on manufacturing facility expansions, production bottlenecks (e.g., autoinjectors), raw material sourcing, and logistics for Eli Lilly, Novo Nordisk, Amgen, and Roche
Cadence daily/weekly
Why it matters Addresses the critical bear point of supply chain constraints, directly impacting the ability of producers to meet surging demand and capitalize on market growth.
Signal to watch Reports of new facility completions, increased production output, and stable supply chains are bullish. Alerts on disruptions or capacity limitations are bearish.
Confidence: high
Metric/field Survey results on endocrinologist, obesity specialist, and primary care physician prescribing patterns, perceptions of new GLP-1 formulations (e.g., oral), and pipeline assets' potential
Cadence quarterly/semi-annually
Why it matters Offers forward-looking insights into how medical professionals view and intend to adopt current and future GLP-1 therapies, influencing market penetration.
Signal to watch Positive physician sentiment towards new GLP-1s, high intent to prescribe, and favorable views on differentiated profiles (e.g., less frequent dosing) are bullish.
Confidence: medium
Metric/field Number and type of job postings for 'GLP-1', 'obesity', 'diabetes', 'manufacturing', 'sales', 'commercialization' roles at Eli Lilly, Novo Nordisk, Amgen, and Roche
Cadence weekly/monthly
Why it matters Indicates strategic investment in scaling operations, market launch preparations, and R&D efforts related to GLP-1 drugs, signaling future growth or shifts in focus.
Signal to watch Increased job postings in manufacturing and commercialization for GLP-1 related roles are bullish, suggesting aggressive market expansion and production scale-up.
Confidence: medium
Metric/field Consensus sales forecasts (peak sales, annual revenue projections) and market share analysis for current and pipeline GLP-1 drugs across indications (obesity, diabetes, NASH, etc.)
Cadence quarterly/annually
Why it matters Provides independent, aggregated market intelligence on the expected financial performance and competitive positioning of GLP-1 assets, aiding in valuation and strategic assessment.
Signal to watch Upward revisions in consensus sales forecasts and projected market share gains for theme members' GLP-1 drugs are bullish.
Confidence: high
| Metric | Cadence | What It Signals | Update Source |
|---|---|---|---|
| Regulatory approval updates | As occurred | Regulatory landscape and potential market entry timing | Google_Sheets |
| Clinical trial outcomes for new indications | Quarterly | Effectiveness and potential market expansion of GLP-1 drugs | Google_Sheets |
| Prescription trends and sales data | Monthly | Market adoption and revenue growth | Google_Sheets |
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type | Catalyst Source |
|---|---|---|---|---|---|---|---|---|---|
| AMGN_17b91ee0 | study completion expected in 2026. | 2026-07-01 | 2026-12-31 | Completion of both Phase III studies for desodoliveb, a CD40 ligand targeting biotherapeutic, in Sjogren's disease. | Study completion is a critical step before data readout and potential regulatory filings, which could position desodoliveb as a significant treatment option in a challenging autoimmune condition. | Ticker | 2026-02-03 | earnings_transcript | AMGN (ticker) |
| AMGN_fe4d51bf | We will update you on those discussions as necessary. | 2026-04-24 | 2026-12-31 | Resolution of ongoing discussions with the FDA regarding TABNIO's (avacopan) following a voluntary withdrawal request related to primary endpoint result readjudication. | The outcome will determine the future commercial viability of TABNIO's, impacting Amgen's rare disease portfolio and potentially leading to a re-evaluation of the product's sales trajectory. | Ticker | 2026-02-03 | earnings_transcript | AMGN (ticker) |
| NVO_af1c28d8 | Q3 2026 | 2026-07-01 | 2026-09-30 | First readout of Ziltivekimab from the ZEUS Phase III trial for ASCVD. | This is a high-potential, first-in-class anti-IL-6 treatment for ASCVD, with positive results potentially opening a large new market and validating a new mechanism of action. | Ticker | 2026-05-06 | earnings_transcript | NVO (ticker) |
| LLY_48d9403d | later this year | 2026-10-01 | 2026-12-31 | Readout of Foundayo Phase 3 trial in obstructive sleep apnea. | Positive results from this trial could lead to a new, high-value indication for Foundayo, further expanding its utility and market potential beyond its current metabolic indications. | Ticker | 2026-08-05 | earnings_transcript | LLY (ticker) |
| LLY_696cb569 | later this year | 2026-10-01 | 2026-12-31 | U.S. regulatory action (approval/decision) for Foundayo in type 2 diabetes. | This regulatory decision would significantly expand Foundayo's addressable market in the U.S. to include type 2 diabetes, a large and established indication, driving substantial revenue growth. | Ticker | 2026-08-05 | earnings_transcript | LLY (ticker) |
| LLY_cf82d1b5 | a few markets late in 2026 | 2026-10-01 | 2026-12-31 | Launch of Orforglipron in a few international markets (e.g., UAE). | This marks the beginning of the international rollout for oral Orforglipron, contributing to global revenue growth and market penetration. | Ticker | 2026-02-04 | earnings_transcript | LLY (ticker) |
| NVO_71e5b33d | at the end of 2026 | 2026-10-01 | 2026-12-31 | FDA regulatory decision for CagriSema in the U.S. for obesity. | Approval would introduce a new, potentially highly effective obesity treatment, strengthening Novo Nordisk's pipeline and competitive position. | Ticker | 2026-05-06 | earnings_transcript | NVO (ticker) |
